The epidemiology of diabetes in psychotic disorders

被引:128
作者
Ward, Martha [1 ]
Druss, Benjamin [1 ,2 ]
机构
[1] Emory Univ, Dept Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA
[2] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
关键词
CARDIOVASCULAR RISK-FACTORS; SERIOUS MENTAL-ILLNESS; QUALITY-OF-CARE; MULTIPLE CHRONIC CONDITIONS; LIFE-STYLE INTERVENTIONS; METABOLIC SYNDROME; HEALTH-CARE; ANTIPSYCHOTIC-DRUGS; ATYPICAL ANTIPSYCHOTICS; SCHIZOPHRENIA SPECTRUM;
D O I
10.1016/S2215-0366(15)00007-3
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Diabetes is highly prevalent in people with psychotic disorders, including schizophrenia and schizoaffective disorders. Exact prevalence is difficult to estimate, since diabetes is often underdiagnosed in people with psychosis. Results of several studies show that the prevalence of diabetes exceeds that in the general population, with documented prevalence in those with psychosis ranging from 1.26% to 50% across studies (median 13%). The association between diabetes and psychosis is complex and multifactorial. Many of the traditional risk factors for disease have increased prevalence in patients with psychotic disorders. In addition to these traditional risk factors, people with psychosis have unique risks that might have additive or even synergistic effects. These risks include the use of antipsychotic medication, the effects of adverse social determinants of health, and genetic loading. Despite evidence that rates of diabetes are increased in individuals with psychosis, many of these patients are not diagnosed or treated, resulting in increased diabetesassociated morbidity and mortality. Specific patient factors, provider issues, and systems-level factors contribute to the treatment gap. Interventions at both the clinical and public health levels are needed to successfully address this problem.
引用
收藏
页码:431 / 451
页数:21
相关论文
共 131 条
[1]   Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia [J].
Ader, Marilyn ;
Garvey, W. Timothy ;
Phillips, Lawrence S. ;
Nemeroff, Charles. B. ;
Gharabawi, Georges ;
Mahmoud, Ramy ;
Greenspan, Andrew ;
Berry, Sally A. ;
Musselman, Dominique L. ;
Morein, Jacqueline ;
Zhu, Young ;
Mao, Lian ;
Bergman, Richard N. .
JOURNAL OF PSYCHIATRIC RESEARCH, 2008, 42 (13) :1076-1085
[2]  
Annis Ann M, 2005, Prev Chronic Dis, V2, pA19
[3]  
Argo T, 2011, ANN CLIN PSYCHIATRY, V23, P117
[4]   Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among central texas veterans [J].
Barner, JC ;
Worchel, J ;
Min, Y .
PHARMACOTHERAPY, 2004, 24 (11) :1529-1538
[5]   A UK audit of screening for the metabolic side effects of antipsychotics in community patients [J].
Barnes, Thomas R. E. ;
Paton, Carol ;
Cavanagh, Mary-Rose ;
Hancock, Elizabeth ;
Taylor, David M. .
SCHIZOPHRENIA BULLETIN, 2007, 33 (06) :1397-1403
[6]   Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study [J].
Barnett, Karen ;
Mercer, Stewart W. ;
Norbury, Michael ;
Watt, Graham ;
Wyke, Sally ;
Guthrie, Bruce .
LANCET, 2012, 380 (9836) :37-43
[7]  
Barnett M, 2010, ANN CLIN PSYCHIATRY, V22, P9
[8]   Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era [J].
Basu, Anirban ;
Meltzer, Herbert Y. .
SCHIZOPHRENIA RESEARCH, 2006, 86 (1-3) :99-109
[9]   Risk of Acute Complications of Diabetes Among People With Schizophrenia in Ontario, Canada [J].
Becker, Taryn ;
Hux, Janet .
DIABETES CARE, 2011, 34 (02) :398-402
[10]  
Behan Caragh, 2008, Irish Journal of Psychological Medicine, V25, P57